search
Back to results

Multidiscipline Care for Acute Kidney Disease (AKD) (AKD)

Primary Purpose

Acute Kidney Injury

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
never received RAAS blockers or received RAAS blockers before AKI.
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Kidney Injury focused on measuring Chronic kidney disease, Acute kidney disease

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 20 years old on the day of index discharge
  2. AKI develops during admission, as defined with KDIGO-AKI Guideline, namely, elevation of serum creatinine above 0.3mg/dL within two days, above 1.5 times baseline and ever receives dialysis during this index hospitalization.
  3. Patients who has KDIGO-AKI stage 2, 3 or who could wean from dialysis requiring AKI-D in the index hospitalization.

Exclusion Criteria:

  1. Baseline estimated glomerular filtration rates (eGFR) less than 5ml/min/1.73m2 or greater than 90ml/min/1.73m2 according to MDRD equation after index discharge.
  2. Patients receive further re-dialysis within 90 days after index hospital discharge, who are withdrawal for AKI-D. (sensors)
  3. Previous gastrointestinal operations.
  4. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of blood transfusion during index admission.
  5. Patients with a chronic lung disease requiring non-invasive or invasive positive pressure ventilation.
  6. Solid organ or hematological transplantation donors.
  7. Evidence of obstructive acute kidney injury.
  8. Systolic blood pressure < 110mmHg.
  9. Pregnant women

Sites / Locations

  • Kaohsiung Medical University Hospital
  • Keelung CGMHRecruiting
  • China Medical University HospitalRecruiting
  • Taichung Veterans General HospitalRecruiting
  • National Taiwan University HospitalRecruiting
  • Taipei Veterans General HospitalRecruiting
  • Linkou Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

never received RAAS blockers or multidiscipline consultation before AKI.

had received RAAS blockers and multidiscipline consultation before AKI.

Arm Description

The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.

All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge. Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).

Outcomes

Primary Outcome Measures

Renal replacement therapy at any time after dialysis
Patients will followed up at any time after dialysis.
survival
Patients will followed up at any time after death.

Secondary Outcome Measures

Rehospitalization
Rehospitalization from myocardial infarction, heart failure, arrhythmia, invasive cardiovascular interventions, cardiovascular causes after noncardiovascular surgery, stroke.

Full Information

First Posted
June 11, 2021
Last Updated
March 6, 2023
Sponsor
National Taiwan University Hospital
Collaborators
Chang Gung Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05064904
Brief Title
Multidiscipline Care for Acute Kidney Disease (AKD)
Acronym
AKD
Official Title
Multidiscipline Care for Acute Kidney Injury to Chronic Kidney Disease Transition (Acute Kidney Disease) - a Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2019 (Actual)
Primary Completion Date
January 6, 2024 (Anticipated)
Study Completion Date
February 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital
Collaborators
Chang Gung Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The Taiwan Consortium of Acute Kidney Injury and Renal Diseases (TCTC) is leading a clinical trial group in Asia-Pacific to reduce the morbidity and mortality associated with acute kidney injury (AKI). The trial is a double two-by-two factorial design that will collect demographic and clinical information of AKI stage 2, 3, or weaning from dialysis-requiring AKI patients (AKI-D) to explore the epidemiology, risk factors and prognosis of AKI in Taiwan. Patients will be randomized either to add Angiotensin-Converting Enzyme Inhibitors (ACE-I)/Angiotensin II Receptor Blocker (ARB) to slow kidney function progression, or to receive multidisciplinary care. Patients will be followed up for a minimum of 6 months to evaluate kidney function, the predictability of developing chronic kidney disease, end stage renal disease, major cardiovascular events, and mortality.
Detailed Description
In the past decade, acute kidney injury (AKI) has emerged as a syndrome of increasing prevalence. Since 2005, hospital-diagnosed cases of AKI have outnumbered those of chronic kidney disease (CKD), and this trend has continued to climb. Patients diagnosed with AKI are at risk for a variety of adverse outcomes, including premature death, morbidity, prolonged hospitalization, and increased medical costs. Potential contributing factors to the development of AKI include pre-existing kidney damage, hemodynamic instability, and the complexity of concurrent medications. As modern medical diagnostic and treatment tools have advanced, the incidence and prevalence of AKI have been steadily rising. The KDIGO Guideline for AKI recommended that we should diagnose AKI if a given patient has a 6 hour urine amount less than 0.5ml/kg/hr or a serum creatinine elevates more than 0.3mg/dL or 1.5 times greater than baselines. Epidemiology data on hospitalized patients indeed disclosed high risk for adverse events using this classification system and its analogues. However, besides diagnosis, we do not have a useful tool to treat or to help improve patient outcomes Acute kidney injury (AKI) is a common complication that affects nearly 5% of hospitalized patients and 40%-70% of patients in the intensive care unit. AKI requiring dialysis (AKI-D), the most severe type of AKI, is associated with the highest proportion of morbidity and mortality. AKI is associated with a risk of end-stage renal disease (ESRD) that is 13 times as high as the risk among patients without AKI, and the risk of ESRD is 40 times as high if the patients have both AKI and pre-existing chronic kidney disease (CKD). Since AKI is recognized as a risk factor for the development of ESRD, it is crucial to have appropriate protection strategies for the avoidance of further target organ damage and associated mortality in the critical phases of the acute kidney disease (AKD). Patients with Acute Kidney Injury (AKI) requiring dialysis (AKI-D) are associated with the highest proportion of morbidity and mortality. AKI is associated with a thirteen-fold higher risk of end-stage renal disease (ESRD) compared to those without AKI, and a forty-fold higher risk if the patient has both AKI and pre-existing chronic kidney disease (CKD). Given the potential for AKI to lead to ESRD, it is essential to develop strategies to protect the target organs from further damage and associated mortality during the acute phase of AKD. Guyton proposed that the kidneys have a crucial role in determining the chronic level of blood pressure (BP), and studies have validated this hypothesis. Furthermore, hospitalization-associated AKI has been identified as an independent risk factor for the development of elevated BP. Elevated BP is a leading risk factor for global health and cardiovascular disease, making it a key element in the pharmacologic treatment and long-term protection of AKD patients. A retrospective analysis of the ICU database, which included 1551 ICU survivors, 611 of which had AKI during their stay, demonstrated a reduced 1-year mortality in those who had AKI and had been prescribed ACEIs/ARBs. To address the gap between acute kidney injury (AKI) and chronic kidney disease (CKD), the Kidney Disease: Improving Global Outcomes (KDIGO) AKI Workgroup has proposed the concept of acute kidney disease (AKD). AKD is defined as a glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m2 or evidence of structural kidney damage that has been present for less than 3 months. This concept provides an integrated bridge between AKI and CKD and also emphasizes the concept of partial renal recovery. It may help to raise awareness and create the necessary clinical mechanisms to follow up AKI survivors for the potential progression to CKD, which has been recently highlighted as a missed opportunity for adequate transitions of care. Furthermore, a panel of gut microbiota and biomarkers will be determined.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
Chronic kidney disease, Acute kidney disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The randomization procedure was developed at the WHI Clinical Coordinating Center and implemented locally through a distributed study database, using a randomized permuted block algorithm, stratified by clinical center site, diabetics mellitus and age group.
Masking
Participant
Masking Description
The randomization procedure was developed at the WHI Clinical Coordinating Center and implemented locally through a distributed study database, using a randomized permuted block algorithm, stratified by clinical center site, diabetics mellitus and age group.
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
never received RAAS blockers or multidiscipline consultation before AKI.
Arm Type
Active Comparator
Arm Description
The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
Arm Title
had received RAAS blockers and multidiscipline consultation before AKI.
Arm Type
Active Comparator
Arm Description
All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge. Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).
Intervention Type
Drug
Intervention Name(s)
never received RAAS blockers or received RAAS blockers before AKI.
Other Intervention Name(s)
Multidiscipline consultation
Intervention Description
Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D). All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.
Primary Outcome Measure Information:
Title
Renal replacement therapy at any time after dialysis
Description
Patients will followed up at any time after dialysis.
Time Frame
MAKE at 180 days
Title
survival
Description
Patients will followed up at any time after death.
Time Frame
MAKE at 180 days
Secondary Outcome Measure Information:
Title
Rehospitalization
Description
Rehospitalization from myocardial infarction, heart failure, arrhythmia, invasive cardiovascular interventions, cardiovascular causes after noncardiovascular surgery, stroke.
Time Frame
MAKE at 180 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 20 years old on the day of index discharge AKI develops during admission, as defined with KDIGO-AKI Guideline, namely, elevation of serum creatinine above 0.3mg/dL within two days, above 1.5 times baseline and ever receives dialysis during this index hospitalization. Patients who has KDIGO-AKI stage 2, 3 or who could wean from dialysis requiring AKI-D in the index hospitalization. Exclusion Criteria: Baseline estimated glomerular filtration rates (eGFR) less than 5ml/min/1.73m2 or greater than 90ml/min/1.73m2 according to MDRD equation after index discharge. Patients receive further re-dialysis within 90 days after index hospital discharge, who are withdrawal for AKI-D. (sensors) Previous gastrointestinal operations. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of blood transfusion during index admission. Patients with a chronic lung disease requiring non-invasive or invasive positive pressure ventilation. Solid organ or hematological transplantation donors. Evidence of obstructive acute kidney injury. Systolic blood pressure < 110mmHg. Pregnant women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vincent Wu, doctor
Phone
886-937-223-278
Email
dr.vincentwu@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincent Wu, doctor
Organizational Affiliation
NTUH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaohsiung Medical University Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
SHANG-JHIH HUANG
Facility Name
Keelung CGMH
City
Keelung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heng-Chih Pan
First Name & Middle Initial & Last Name & Degree
Heng-Chih Pan
Facility Name
China Medical University Hospital
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ya-Fei Yang
First Name & Middle Initial & Last Name & Degree
Ya-Fei Yang
First Name & Middle Initial & Last Name & Degree
Ping-Chin Lai
Facility Name
Taichung Veterans General Hospital
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming-Ju Wu
First Name & Middle Initial & Last Name & Degree
Ming-Ju Wu
First Name & Middle Initial & Last Name & Degree
JYUN-DE HUANG
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent Wu, doctor
Phone
886-937223278
Email
dr.vincentwu@gmail.com
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Der-Cherng Tarng
First Name & Middle Initial & Last Name & Degree
Der-Cherng Tarng
First Name & Middle Initial & Last Name & Degree
GUO-HUA LI
Facility Name
Linkou Chang Gung Memorial Hospital
City
Taoyuan
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
CHIH-HSIANG CHANG
First Name & Middle Initial & Last Name & Degree
CHIH-HSIANG CHANG
First Name & Middle Initial & Last Name & Degree
JI-TSENG FANG
First Name & Middle Initial & Last Name & Degree
YUNG-CHANG CHEN
First Name & Middle Initial & Last Name & Degree
HSIANG-HAO HSU
First Name & Middle Initial & Last Name & Degree
MING JEN CHAN
First Name & Middle Initial & Last Name & Degree
KUAN-HSING CHEN
First Name & Middle Initial & Last Name & Degree
CHENG-HAO WENG
First Name & Middle Initial & Last Name & Degree
HUANG-YU YANG
First Name & Middle Initial & Last Name & Degree
Ching Chung Hsiao
First Name & Middle Initial & Last Name & Degree
MING-YANG CHANG
First Name & Middle Initial & Last Name & Degree
CHAN-YU LIN
First Name & Middle Initial & Last Name & Degree
WEN-HUNG HUANG
First Name & Middle Initial & Last Name & Degree
TSUNG-YU TSAI
First Name & Middle Initial & Last Name & Degree
CHING-WEI HSU
First Name & Middle Initial & Last Name & Degree
YA-CHUNG TIAN
First Name & Middle Initial & Last Name & Degree
YI-JUNG LI
First Name & Middle Initial & Last Name & Degree
CHANG-CHI CHENG
First Name & Middle Initial & Last Name & Degree
LI-CHENG WU

12. IPD Sharing Statement

Learn more about this trial

Multidiscipline Care for Acute Kidney Disease (AKD)

We'll reach out to this number within 24 hrs